Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 15/20 | 0.82 |
| ▸ | AR | P10275 | 4/20 | 0.61 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610801 | 0.94 | PGR (0.85) | PGRAR | |
| SCHEMBL4609938 | 0.90 | PGR (1.00) | PGRAR | |
| SCHEMBL4613063 | 0.87 | PGR (0.81) | PGRAR | |
| SCHEMBL4610915 | 0.87 | PGR (0.83) | PGRARAURKAKDRAURKB | |
| SCHEMBL4610121 | 0.85 | PGR (0.82) | PGRAR | |
| SCHEMBL4660413 | 0.83 | PGR (1.00) | PGRAR | |
| SCHEMBL4610876 | 0.82 | PGR (0.86) | PGRAR | |
| SCHEMBL4611092 | 0.81 | PGR (0.85) | PGRARAURKAKDRAURKB | |
| SCHEMBL4598279 | 0.80 | PGR (0.84) | PGRAR | |
| SCHEMBL4599081 | 0.80 | PGR (0.77) | PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909785-A2 | USE OF PROGESTERONE RECEPTOR MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-16 | — | — | EP | claimed |
| US-7291643-B2 | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | WYETH (US) | 2007-11-06 | — | — | US | claimed |
| WO-2007016385-A2 | USE OF SUBSTITUTED 5-AMINO-1H-PYRROLE-2-CARBONITRILE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027201-A1 | Use of progesterone receptor modulators | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | WYETH (US) | 2007-02-01 | — | — | US | claimed |
| EP-1909785-A2 | USE OF PROGESTERONE RECEPTOR MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910285-A1 | CYANOPYRROLE-SULFONAMIDE PROGESTERONE RECEPTOR MODULATORS AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7291643-B2 | Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof | WYETH (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007016385-A2 | USE OF SUBSTITUTED 5-AMINO-1H-PYRROLE-2-CARBONITRILE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016212-A1 | CYANOPYRROLE-SULFONAMIDE PROGESTERONE RECEPTOR MODULATORS AND USES THEREOF | WYETH (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027201-A1 | Use of progesterone receptor modulators | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027201-A1 | Use of progesterone receptor modulators | GNRHR, PGR, FSHR | PGR 2/4885AR 28/4885AURKA 3517/4885 |
| US-20070027126-A1 | E.g., N-[4-(5-cyano-1-methyl-1H-pyrrol-2-yl)phenyl]propane-1-sulfonamide and tert-butyl 2-cyano-5-{4-{(ethylsulfonyl)amino]phenyl}-1H-pyrrole-1-carboxylate; useful for contraception and hormone replacement therapy | GNRHR, PGR, PRLHR | PGR 2/4885AR 165/4885AURKA 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.